Backed by top investors such as ARK Invest, Sequoia Capital, and Thrive Capital, Neuralink’s Series E funds will accelerate human trials of its BCI devices in the U.S., Canada, and UAE. The FDA recently granted breakthrough device designation to Neuralink’s speech-restoration and vision-restoration implants. Early trial results already demonstrate paralyzed patients controlling cursors and prosthetic limbs via thought, and the new funding round aims to scale these programs globally.

Source:
TechCrunch – Full Article